Xponance Inc. Sells 6,418 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Xponance Inc. trimmed its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 48.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,774 shares of the specialty pharmaceutical company’s stock after selling 6,418 shares during the quarter. Xponance Inc.’s holdings in Jazz Pharmaceuticals were worth $723,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Hsbc Holdings PLC boosted its position in shares of Jazz Pharmaceuticals by 2,454.2% during the fourth quarter. Hsbc Holdings PLC now owns 49,117 shares of the specialty pharmaceutical company’s stock valued at $5,993,000 after buying an additional 47,194 shares during the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Jazz Pharmaceuticals by 59.0% during the 4th quarter. Allianz Asset Management GmbH now owns 24,640 shares of the specialty pharmaceutical company’s stock valued at $3,031,000 after acquiring an additional 9,146 shares during the last quarter. Bank of Nova Scotia grew its stake in shares of Jazz Pharmaceuticals by 565.9% in the fourth quarter. Bank of Nova Scotia now owns 11,153 shares of the specialty pharmaceutical company’s stock worth $1,372,000 after acquiring an additional 9,478 shares during the period. Eagle Asset Management Inc. bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $2,179,000. Finally, APG Asset Management US Inc. purchased a new stake in Jazz Pharmaceuticals in the fourth quarter worth approximately $1,389,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 0.7 %

NASDAQ JAZZ opened at $110.93 on Monday. The stock has a market cap of $7.00 billion, a PE ratio of 22.87, a P/E/G ratio of 1.36 and a beta of 0.57. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $137.38. The stock’s 50 day moving average is $111.02 and its 200 day moving average is $110.79.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating the consensus estimate of $3.80 by $0.87. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. Research analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 4.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several research analyst reports. Piper Sandler lowered their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Royal Bank of Canada lowered their price objective on shares of Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $205.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.